EGFR and non-small cell lung carcinoma: also reported that clearing of all EGFR cfDNA after osimertinib treatment predicts the efficacy of Osimertinib with significant improvement in PFS, ORR, and DCR in 82 patients with NSCLC using Cobas® EGFR mutation test v2 (27).